...
首页> 外文期刊>Biomarkers in medicine >Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers
【24h】

Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers

机译:新兴靶向帕金森病的靶向:对系统性生物标志物的检查

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Parkinson's disease (PD) is a highly prevalent and irreversible neurodegenerative disorder that is typically diagnosed in an advanced stage. Currently, there are no approved biomarkers that reliably identify PD patients before they have undergone extensive neuronal damage, eliminating the opportunity for future disease-modifying therapies to intervene in disease progression. This unmet need for diagnostic and therapeutic biomarkers has fueled PD research for decades, but these efforts have not yet yielded actionable results. Recently, studies exploring mechanisms underlying PD progression have offered insights into multisystemic contributions to pathology, challenging the classic perspective of PD as a disease isolated to the brain. This shift in understanding has opened the door to potential new biomarkers from multiple sites in the body. This review focuses on emerging candidates for PD biomarkers in the context of current diagnostic approaches and multiple organ systems that contribute to disease.
机译:帕金森病(PD)是一种高度普遍性和不可逆转的神经变性障碍,通常被诊断为晚期。目前,没有经批准的生物标志物可在经历广泛的神经元损伤之前可靠地识别PD患者,从而消除了未来疾病改性疗法的机会,介入疾病进展。这种未满足的诊断和治疗生物标志物的需求已经推动了几十年的PD研究,但这些努力尚未产生可行的结果。最近,PD进展探索机制的研究已经向病理学的多系统贡献提供了见解,具有挑战PD作为脑梗塞疾病的经典视角。这种理解的转变已经向身体中的多个位点开辟了潜在的新生物标志物。本综述重点介绍了在当前诊断方法和多个器官系统中产生PD生物标志物的新兴候选人,以及有助于疾病的多个器官系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号